Latest On Astellas Pharma Inc (ALPMY):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-01 16:16 EST | News | IVERIC Bio jumps 18% on acquisition by Astellas Pharma | N/A |  |
| 2023-03-29 05:46 EST | News | Astellas, Roche Diabetes collaborate to integrate Accu-Chek with BlueStar app | N/A | |
| 2023-02-06 11:39 EST | News | Astellas Pharma announces management changes | N/A | |
| 2022-11-16 04:22 EST | News | Astellas' fezolinetant to treat menopause symptoms gets EMA review | N/A | |
| 2022-11-16 04:22 EST | News | Astellas, Pantherna expand collaboration on mRNA-based regenerative medicine programs | N/A | |
| 2022-11-16 04:20 EST | News | Taysha Gene stock soars 36% as Astellas to pick 15% stake for $50M | N/A | |
| 2022-11-16 04:20 EST | News | Astellas Pharma Inc. (ALPMF) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-03-09 16:09 EST | News | Astellas Worth A Look On Revenue Re-Acceleration Potential | N/A | |
| 2021-12-17 14:12 EST | News | Seagen, Astellas Pharma's enfortumab vedotin wins positive CHMP opinion for urothelial cancer | N/A | |
| 2021-09-27 07:26 EST | News | Seagen, Astellas' Padcev OK'd in Japan for advanced urothelial cancer | N/A | |
| 2021-07-31 00:48 EST | News | Astellas and Minovia Therapeutics ink strategic collaboration and license agreement | N/A | |
| 2021-03-26 19:11 EST | News | Astellas and Pfizer's XTANDI gets EMA positive opinion for additional indication | N/A | |
| 2021-01-30 16:59 EST | Financials | Company financials have been released. | Neutral | |
| 2021-01-06 13:30 EST | News | FDA grants two priority reviews to Astellas' bladder control treatment | N/A | |
| 2020-12-07 15:52 EST | News | KaliVir Immunotherapeutics inks agreement with Astellas for development and commercialization of VET2-L2 | N/A | |
| 2020-11-26 22:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 01:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-02 19:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-01 07:44 EST | News | Astellas Pharma ADR reports 1H results | N/A | |
| 2020-09-26 14:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 06:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 10:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-07 14:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 10:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 18:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 06:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 22:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 14:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 19:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 10:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 18:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 02:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 14:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 06:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 07:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 07:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-22 14:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 02:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 07:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 18:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-20 06:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-09 22:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-03 22:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-25 22:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 05:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-27 23:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-22 01:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-21 00:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-18 01:05 EST | Financials | Company financials have been released. | Neutral | |
About Astellas Pharma Inc (ALPMY):
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
General
- Name Astellas Pharma Inc
- Symbol ALPMY
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-General
- Full Time Employees 15,883
- Last Split Factor125:100
- Last Split Date2014-04-02
- Fiscal Year EndMarch
- Web URLhttp://www.astellas.com
View More
Valuation
- Trailing PE 19.26
- Forward PE 13.72
- Price/Sales (Trailing 12 Mt.) 2.7
- Price/Book (Most Recent Quarter) 2.47
- Enterprise Value Revenue 0.02
- Enterprise Value EBITDA 0.11
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 11%
- Return on Assets 5%
- Return on Equity 10%
- Earnings Per Share $0.85
- Revenue Per Share $0
- Gross Profit 1.02 trillion
- Quarterly Earnings Growth -3.7%
View More
Highlights
- Market Capitalization 30.47 billion
- Analyst Target Price $50
- Book Value Per Share $6.06
View More
Share Statistics
- Shares Outstanding 1.86 billion
- Shares Float 1.86 billion
- % Held by Insiders <1%
- % Held by Institutions 0.21%
View More
Technicals
- Beta 0.56
- 52 Week High $18.43
- 52 Week Low $12.32
- 50 Day Moving Average 16.67
- 200 Day Moving Average 15.42
View More
Dividends
- Forward Annual Dividend Rate $0.39
- Forward Annual Dividend Yield 2.32%
- Payout Ratio 19%
- Dividend Date 2016-12-15
- ExDividend Date 2020-09-28
- Dividend Per Share $0.34
- Dividend Yield 0%
View More
Astellas Pharma Inc (ALPMY) Dividend Calendar:
ALPMY's last dividend payment was made to shareholders on December 15, 2016.
Astellas Pharma Inc pays out 19% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Astellas Pharma Inc (ALPMY) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-01-29 | $N/A | $0.31 | ||
| 2020-09-30 | 2020-12-31 | $N/A | $0.31 | ||
| 2020-06-30 | 2020-09-30 | $N/A | $0.11 | ||
| 2020-03-31 | 2020-06-30 | $N/A | $0.25 | ||
| 2019-12-31 | 2020-03-31 | $338.07 billion | $0.03 | ||
| 2019-09-30 | 2019-12-31 | $316.34 billion | $0.30 | ||
| 2019-06-30 | 2019-09-30 | $334.13 billion | $0.34 | ||
| 2019-03-31 | 2019-06-30 | $301.32 billion | $0.29 | ||
| 2018-12-31 | 2019-03-31 | $357.93 billion | $0.15 | ||
| 2018-09-30 | 2018-12-31 | $4.89 billion | $0.42 | ||
| 2018-06-30 | 2018-09-30 | $383.01 billion | $0.22 | ||
| 2018-03-31 | 2018-06-30 | $5.23 billion | $0.25 | ||
| 2017-12-31 | 2018-03-31 | $431.96 billion | $0.10 | ||
| 2017-09-30 | 2017-12-31 | $2.81 billion | $0.27 | ||
| 2017-06-30 | 2017-09-30 | $322.57 billion | $0.17 | ||
| 2017-03-31 | 2017-06-30 | $306.08 billion | $0.18 | ||
| 2016-12-31 | 2017-03-31 | $353.92 billion | $0.17 | ||
| 2016-09-30 | 2016-12-31 | $313.92 billion | $0.26 | ||
| 2016-06-30 | 2016-09-30 | $337.75 billion | $0.22 | ||
| 2016-03-31 | 2016-06-30 | $307.04 billion | $0.30 | ||
| 2015-12-31 | 2016-03-31 | $0.12 | |||
| 2015-09-30 | 2015-12-31 | $0.24 | |||
| 2015-06-30 | 2015-09-30 | $0.22 | |||
| 2015-03-31 | 2015-06-30 | $0.17 | |||
| 2014-12-31 | 2015-03-31 | $0.08 | |||
| 2014-09-30 | 2014-12-31 | $0.17 | |||
| 2014-06-30 | 2014-09-30 | $0.14 | |||
| 2014-03-31 | 2014-06-30 | $0.16 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $0.04 | |||
| 2013-09-30 | 2013-12-31 | $0.14 | |||
| 2013-06-30 | 2013-09-30 | $0.12 | |||
| 2013-03-31 | 2013-06-30 | $0.10 | |||
| 2012-12-31 | 2013-03-31 | -$0.01 | |||
| 2012-09-30 | 2012-12-31 | $0.14 | |||
| 2012-06-30 | 2012-09-30 | $0.12 | |||
| 2012-03-31 | 2012-06-30 | $0.19 | |||
| 2011-12-31 | 2012-03-31 | -$0.11 | |||
| 2011-09-30 | 2011-12-31 | $0.27 | |||
| 2011-06-30 | 2011-09-30 | $0.15 | |||
| 2011-03-31 | 2011-06-30 | $0.13 | |||
| 2010-12-31 | 2011-03-31 | -$0.06 | |||
| 2010-09-30 | 2010-12-31 | $0.19 | |||
| 2010-06-30 | 2010-08-02 | $0.19 | |||
| 2010-03-31 | 2010-05-12 | $0.03 | |||
| 2009-03-31 | 2009-05-13 | $0.08 | -$0.27 | 130.07% | |
| 2008-12-31 | 2009-02-02 | $0.27 |
Astellas Pharma Inc (ALPMY) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 54.78 billion |
| Income Before Tax | N/A | N/A | N/A | N/A | 77.6 billion |
| Selling General Administrative | N/A | N/A | N/A | N/A | 127.51 billion |
| Gross Profit | N/A | N/A | N/A | N/A | 255.3 billion |
| Ebit | N/A | N/A | N/A | N/A | 76.15 billion |
| Operating Income | N/A | N/A | N/A | N/A | 76.15 billion |
| Income Tax Expense | 15.06 billion | 6.43 billion | 9.83 billion | 775 million | 16.11 billion |
| Total Revenue | N/A | N/A | N/A | N/A | 338.07 billion |
| Cost of Revenue | N/A | N/A | N/A | N/A | 82.77 billion |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 1.45 billion |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | 61.49 billion |
| Net Income Applicable to Common Shares | 60.08 billion | 22.43 billion | 50.41 billion | 5.39 billion | 61.49 billion |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | -20.58 billion | -30.22 billion | 21.32 billion | -18.17 billion | 20.48 billion |
| Total Cash Flow from Investing Activities | -9.96 billion | -28.33 billion | -315.41 billion | -27.83 billion | -32.57 billion |
| Net Borrowings | -36.23 billion | -34.3 billion | 320.98 billion | -4.44 billion | -4.2 billion |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | -79.28 billion | -5.6 billion |
| Change to Operating Activities | 10.56 billion | -10.56 billion | 1.72 billion | -12.12 billion | -31.57 billion |
| Change in Cash | N/A | N/A | N/A | -33.77 billion | 51.95 billion |
| Total Cash from Operating Activities | 93.36 billion | 21.6 billion | 51.71 billion | 68.63 billion | 94.25 billion |
| Depreciation | N/A | N/A | N/A | 17.15 billion | 14.13 billion |
| Other Cash Flow from Investing Activities | -150 million | 6.59 billion | 13.64 billion | -2.54 billion | -10.79 billion |
| Change to Inventory | N/A | N/A | N/A | 3.6 billion | -1.1 billion |
| Change to Account Receivables | N/A | N/A | N/A | -22.49 billion | 15.07 billion |
| Other Cash Flow from Financing Activities | -532 million | -645 million | 153 million | -261 million | -4.42 billion |
| Change to Net Income | 31.67 billion | 10.39 billion | -2.82 billion | 39.18 billion | -7.82 billion |
| Capital Expenditures | N/A | N/A | N/A | 14.52 billion | 9.22 billion |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 672.33 billion |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 1.32 trillion |
| Other Current Liabilities | 359.85 billion | 503.42 billion | N/A | N/A | 326.2 billion |
| Total Assets | N/A | N/A | N/A | N/A | 1.99 trillion |
| Common Stock | 103 billion | 103 billion | 103 billion | 103 billion | 103 billion |
| Other Current Assets | 19.24 billion | 22.73 billion | N/A | N/A | 19.04 billion |
| Retained Earnings | 963.01 billion | 941.85 billion | 918.89 billion | 905.85 billion | 949.85 billion |
| Other Liabilities | 292.39 billion | 290.46 billion | 301.68 billion | 230.28 billion | 206.28 billion |
| Other Assets | 95.41 billion | 99.45 billion | 99.81 billion | 97.07 billion | 127.31 billion |
| Cash | N/A | N/A | N/A | N/A | 277.6 billion |
| Total Current Liabilities | 635.85 billion | 616.93 billion | N/A | N/A | 466.06 billion |
| Other Stockholder Equity | 132.14 billion | 114.64 billion | 115.03 billion | 109.99 billion | 129.75 billion |
| Property, Plant & Equipment | 255.18 billion | 265.67 billion | 267.11 billion | 268.6 billion | 260.9 billion |
| Total Current Assets | 863.29 billion | 819.9 billion | N/A | N/A | 834.15 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 85.09 billion |
| Net Tangible Assets | 403.65 billion | 368.93 billion | 300.41 billion | 283.15 billion | 635.12 billion |
| Short Term Investments | N/A | N/A | N/A | N/A | 4.54 billion |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | 155.74 billion | 155.74 billion | N/A | N/A | 149.28 billion |
| Accounts Payable | 111 billion | 113.51 billion | N/A | N/A | 139.86 billion |
Astellas Pharma Inc (ALPMY) Chart:
Astellas Pharma Inc (ALPMY) News:
Below you will find a list of latest news for Astellas Pharma Inc (ALPMY) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Astellas Pharma Inc (ALPMY) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Astellas Pharma Inc (ALPMY) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2008-10-21 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1446390/000101915508000579/0001019155-08-000579-index.htm |
| 2013-05-13 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1446390/000101915513000253/0001019155-13-000253-index.htm |
| 2014-04-02 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1446390/000101915514000133/0001019155-14-000133-index.htm |
| 2008-10-10 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1446390/000110465908063346/0001104659-08-063346-index.htm |
| 2008-10-27 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1446390/000119380508002488/0001193805-08-002488-index.htm |
| 2013-02-13 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1446390/000119380513000347/0001193805-13-000347-index.htm |
| 2013-05-03 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1446390/000119380513000881/0001193805-13-000881-index.htm |
| 2013-05-06 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1446390/000119380513000898/0001193805-13-000898-index.htm |
| 2013-05-13 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1446390/000119380513000938/0001193805-13-000938-index.htm |
| 2014-03-20 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1446390/000119380514000509/0001193805-14-000509-index.htm |
| 2014-03-24 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1446390/000119380514000557/0001193805-14-000557-index.htm |
| 2014-03-24 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1446390/000119380514000561/0001193805-14-000561-index.htm |
| 2017-09-29 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1446390/000119380517002836/0001193805-17-002836-index.htm |
| 2017-12-21 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1446390/000119380517003626/0001193805-17-003626-index.htm |
| 2019-11-22 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1446390/000119380519001576/0001193805-19-001576-index.htm |
| 2014-10-15 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1446390/000157104914005109/0001571049-14-005109-index.htm |